Tatva Chintan Q2FY27 revenue up 76% YoY to ₹2,173 Mn, PAT up 116%
Q2FY27 revenue up 76% YoY to ₹2,173 Mn, EBITDA up 83% to ₹407 Mn, PAT up 116% to ₹215 Mn.
By ScoutQuest · · 1 min read
- Q2FY27 Revenue
- ₹2,173 Mn versus ₹1,235 Mn a year earlier (up 76%)
- Q2FY27 EBITDA
- ₹407 Mn (19% margin), up 83% YoY
- Q2FY27 PAT
- ₹215 Mn (9.9% margin, up 116%)
- Period
- Q2FY27 and H1FY27 (quarter and half year ended…
- Positioning
- Tatva Chintan describes itself as a diversified specialty chemical maker across PTC, SDA, electrolyte salts and pharma/agro/speciality chemicals, serving customers across a wide spectrum of chemical industries.
📈 Q2FY27 revenue from operations was ₹2,173 Mn versus ₹1,235 Mn a year earlier (up 76%), with EBITDA excluding other income of ₹407 Mn (19% margin) and PAT of ₹215 Mn (9.9% margin, up 116%). H1FY27 revenue was ₹3,844 Mn (up 60%) and PAT ₹374 Mn (up 126%), with EPS of ₹16.00.
📌 The company positions itself across four product categories; SDA was the largest in H1FY27 at ₹1,546 Mn, followed by PASC at ₹1,247 Mn. Management says EURO 7 emission standards are already contributing meaningfully to SDA sales.
🔬 Management states that hybrid-battery electrolyte applications are progressing toward commercialisation, recently launched agro and pharma products are contributing, and all five semiconductor chemical products are advancing through development and customer qualification.
🏭 The company says its new greenfield project is on schedule and will provide capacity for organic growth and new molecules. Leverage has risen: short-term borrowings were ₹1,655.30 Mn at 30-Sep-26 and debt to EBITDA is shown at 4.30x for H1FY27.
Also from Tatva Chintan Pharma Chem
Tatva Chintan Pharma shares fell about 10% to their lowest level in 23 sessions
22 Oct 2026
Tatva Chintan Pharma rose on good numbers and is holding up even in a weak market; a guest said the trend is positive and gave a hold call
21 Oct 2026
Updated Investor Presentation: H1FY27 RoE revised to 6.3%, Debt to EBITDA to 1.16
19 Oct 2026
More numbers
- Revenue from operations, Q2FY272,173 (₹ Mn)
- Revenue growth YoY, Q2FY2776%
- EBITDA (excl. other income), Q2FY27407 (₹ Mn)
- Profit after tax, Q2FY27215 (₹ Mn)
- PAT growth YoY, Q2FY27116%
- Revenue from operations, H1FY273,843.75 (₹ Mn)
- Profit after tax, H1FY27374.32 (₹ Mn)
- EPS, H1FY2716.00
- Revenue from operations, FY265,058.58 (₹ Mn)
- Short-term borrowings, 30-Sep-261,655.30 (₹ Mn)
- Tangible net worth, 30-Sep-268,146.51 (₹ Mn)
- SDA revenue, H1FY271,546 (In ₹ Mn.)
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.